AZN Jan 2025 80.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:30PM EDT. Market open.
Loading interactive chart...
- Business Wire
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
WILMINGTON, Del., September 08, 2024--Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s proprietary computational pathology platform, quantitative continuous scoring (QCS), was predictive of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who were treated with datopotamab deruxtecan (Dato-DXd). In patients with TROP2-QCS biomarker positive tumors, datopotamab deruxtecan demonstrated a
- The Guardian
China detains five AstraZeneca staff over ‘data privacy and import breaches’
Detentions involve Chinese citizens who marketed cancer drugs for firm’s oncology division
- The Telegraph
AstraZeneca staff detained in China amid claims of illegal drug imports
Five AstraZeneca staff have been detained in China amid claims of potential illegal activity at the British drug giant.
© 2024 Yahoo. All rights reserved.